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Summary
Background: Increasing prevalence of diabetes
worldwide is projected to lead to an increase in pa-
tients with end-stage renal disease (ESRD) requiring
renal replacement therapy (RRT).
Aim: To provide contemporary estimates of the
prevalence of ESRD and requirement for RRT
among people with diabetes in a nationwide study
and to report associated survival.
Methods: Data were extracted and linked from three
national databases: Scottish Renal Registry, Scottish
Care Initiative-Diabetes Collaboration and National
Records of Scotland death data. Survival analyses
were modelled with Cox regression.
Results: Point prevalence of chronic kidney disease
(CKD)5 in 2008 was 1.63% of 19 414 people with
type 1 diabetes (T1DM) compared with 0.58% of
167 871 people with type 2 diabetes (T2DM) (odds
ratio for DM type 0.97, P=0.77, on adjustment for
duration. Although 83% of those with T1DM and
CKD5 and 61% of those with T2DM and CKD5
were receiving RRT, there was no difference when
adjusted for age, sex and DM duration (odds ratio for
DM type 0.83, P=0.432). Diabetic nephropathy
was the primary renal diagnosis in 91% of people
with T1DM and 58% of people with T2DM on RRT.
Median survival time from initiation of RRT was
3.84 years (95% CI 2.77, 4.62) in T1DM and 2.16
years (95% CI: 1.92, 2.38) in T2DM.
Conclusion: Considerable numbers of patients with
diabetes continue to progress to CKD5 and RRT.
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Almost half of all RRT cases in T2DM are considered
to be due to conditions other than diabetic nephro-
pathy. Median survival time for people with diabetes
from initiation of RRT remains poor. These preva-
lence data are important for future resource
planning.
Introduction
The prevalence of diabetes worldwide has increased
dramatically in recent years and is projected to
reach over 552 million cases by 2030.1 In
Scotland, the recorded prevalence of diabetes has
increased substantially from 2.6%2 in 2003 to
4.7%3 in 2011. This increase in prevalence of dia-
betes is projected to lead to a significant increase in
patients with end-stage renal disease (ESRD) requir-
ing renal replacement therapy (RRT).4 Incidence of
new patients commencing RRT in 2011 in Scotland
was 96 per million population (pmp) with 24% of
patients with diabetes as their primary renal diagno-
sis (PRD) between 2007 and 2011.5 UK Registry in-
cidence was 108 pmp with 25% diabetes as PRD in
their 2011 incident cohort.6 In the UK renal registry
comorbidity data are reported in 55% of all those
with RRT and among these 35% either have dia-
betes as the PRD or report it as a comorbid condi-
tion.7 However, to predict this future burden on
healthcare and resources and to gauge whether out-
comes in those with diabetes are changing, accurate
estimates of current prevalence among those with
diabetes would be useful but this cannot be directly
obtained from current reports.
The aim of this study was first to examine the
prevalence of patients with chronic kidney disease
(CKD)5 and patients receiving RRT in all diabetics
within Scotland, UK and ascertain the PRD of these
patients. Second, we examined survival in these pa-
tients and whether PRD was related to survival after
the initiation of RRT.
Methods
All patients diagnosed with diabetes until 31 May
2008 in Scotland, UK were included in the analysis.
Data were linked between the following relevant
datasets: Scottish Renal Registry (SRR),5 the
Scottish Care Initiative-Diabetes Collaboration
(SCI-DC)8 and the National Records of Scotland
death data by the National Health Service
Information Services Division. Records for all those
ever registered as having diabetes in the SCI-DC
database by 31 May 2008 were extracted and
linked to the SRR and National Records of
Scotland death data. Diabetes type was determined
by the clinician recording the diagnosis on the SCI-
DC database but with the additional requirement
that the prescription history did not contradict this
(i.e. no evidence of lengthy period of diabetes
before insulin and no co-prescribing of nonmetfor-
min oral diabetes drugs.9
Data sources
All patients with diabetes are registered on a single
Nationwide Clinical Record System; the SCI-DC
database which was rolled out nationwide from
2002 onwards. Registration occurs automatically
when a patient is diagnosed with diabetes and as-
signed a corresponding Read code for diabetes in a
primary care practice or a hospital-based diabetes
clinic. Read codes are standardized codes used to
record clinical data in primary care in the UK and
are used to evaluate clinical performance, inform
payment tariffs in primary care and allow inclusion
into the national retinopathy screening programme.
All but five of 1000 general practitioner practices
in Scotland are linked to the register and so the data-
base is estimated to capture over 99% of all patients
nationally assigned a read code for diabetes.
The SRR records the assigned PRD, methods of
treatment and outcomes of all patients receiving
RRT in Scotland. Patients are registered when RRT
first commenced. The SRR was started in 1991 and
was back filled to 1960 when regular and routine
RRT was initiated, using the European Renal
Association—European Dialysis and Transplant
Association (ERA-EDTA) registry. The SRR currently
captures data from all of the nine adult and one
paediatric renal unit in Scotland in addition to all
24 satellite dialysis units, thereby achieving 100%
national coverage.
The PRD is recorded by the nephrologist respon-
sible for the care of the patient using ERA-EDTA
PRD codes. PRDs were grouped into five
categories—primary glomerulonephritis, interstitial
nephropathies, multisystem disease, diabetic
nephropathy and ‘not known and other’.10 The not
known and other group constitutes mostly those pa-
tients for whom it has not been possible to deter-
mine the PRD. A PRD of diabetic nephropathy is
often based on the clinical judgement of the neph-
rologist and not proven by a renal biopsy. Renal
biopsy is only performed when there is clinical
doubt about the diagnosis of diabetic nephropathy
due to the potential risks involved.
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Data from individuals who were alive and diag-
nosed with diabetes on or before 31 May 2008
were analysed to provide the point prevalence in
order to allow examination of the current level of
renal disease burden. Individuals were identified as
having CKD5 (estimated glomerular filtration rate
[eGFR]< 15ml/min/1.73m2 or on RRT) using
either modification of diet in renal disease11 derived
eGFR readings obtained from the SCI-DC database
or if they were receiving RRT on the 31 May 2008 as
determined from the SRR. Only individuals with a
minimum of two eGFR readings of <15ml/min/
1.73m2 occurring at least 3 months apart in the 2
years prior to 31 May 2008 or in the 6 months after
were included to minimize the risk of misclassifying
acute kidney injury.
Survival
An incident cohort of RRT recipients was selected to
examine whether survival varied by PRD. This com-
prises those individuals in the diabetes SRR database
extract who had first received RRT between 1
January 2006 and 13 January 2011. Records were
linked to National Records of Scotland death data
allowing mortality follow-up to the 13 January 2011.
Statistical methods
Univariate tests of differences in the proportion of
those with diabetes who were receiving RRT by dia-
betes type and by sex were carried out using Chi-
squared tests with subsequent adjustment for
possible confounders using logistic regression mod-
els. Cox regression survival analysis was used to de-
termine whether survival from initiation of RRT
varied by assigned PRD. All analyses were per-
formed using R version 2.15.1.
Ethics statement
Approval for data linkage was obtained from the
Scotland A Research Ethics Committee, Caldicott
(data privacy) Guardian for the 14 Scottish Health
Boards and the National Health Service Information
Services Division Privacy Advisory Committee.
Results
A total of 206 303 individuals were identified as
having diabetes and being alive on the 31 May
2008 (Figure 1). A total of 18 091 (8.8%) did not
have sufficient eGFR measurements to determine
eGFR status. Of these, 148 were receiving RRT
and so were included in the analysis (the remaining
17 943 individuals were excluded). In those with
sufficient eGFR measurement, the median number
of eGFR readings recorded was 5 (interquartile
range 3–8) between the 2 years prior to 31 May
2008 up to 6 months after. A further 1075 individ-
uals were also excluded as they had other forms of
diabetes not relevant to this study.
Point prevalence of CKD5
On 31 May 2008, there were 187 285 people in
Scotland with known eGFR status registered as
having type 1 diabetes (T1DM) or type 2 diabetes
(T2DM). A total of 1288 of these had CKD5. Overall,
1.63% of those with T1DM had CKD5 compared
with 0.58% of those with T2DM. The odds ratio
for CKD5 in T1DM vs. T2DM was 4.24 (95% CI:
3.62, 4.96, P< 0.001) but was near unity and
nonsignificant when adjusted for the much longer
diabetes duration in T1DM than T2DM (odds ratio
for type of diabetes 0.97; 95% CI: 0.80, 1.18,
P=0.77, on adjustment for duration).
There was no difference in the prevalence of
CKD5 by sex in those with T2DM (odds ratio for
sex 0.91; 95% CI: 0.80, 1.03, P=0.13). However,
for those with T1DM there was a slight preponder-
ance of CKD5 in men: the odds ratio adjusted for
age and diabetes duration was 1.25 (95% CI: 1.00,
1.58, P=0.05).
Point prevalence of RRT
In Scotland, 1.35% of individuals with T1DM and
0.35% of those with T2DM were receiving RRT on
31 May 2008 (Table 1). These figures equate to 83%
of those with T1DM and CKD5 and 61% of those
with T2DM and CKD5. The difference in rate of RRT
by type was not significant (odds ratio for diabetes
type 0.83, P=0.43) on adjustment for age, sex and
diabetes duration.
The proportion of those with CKD5 in receipt
of RRT decreased by age: 86% of those aged 50
years received RRT; 71% of those aged 51–75
years; and 39% of those over 75 years. The odds












1,075 (0.01%) with 
forms of diabetes not 
relevant to the study 
Figure 1. Identification of records included in study.
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ratio per year for the trend adjusted for sex, duration
and diabetes type was 0.94 (95% CI: 0.93, 0.95,
P< 0.001).
Of those with CKD5, a greater proportion of men
(73%) than women (58%) were receiving RRT (odds
ratio for sex adjusted for age, diabetes duration and
diabetes type: 1.72; 95% CI: 1.34, 2.21, P< 0.001).
PRDs in those with diabetes receiving RRT
The designated PRD was unobtainable for 24 (2.9%)
people with diabetes receiving RRT (6 patients with
T1DM and 79 people with T2DM). A total of 91% of
patients with T1DM had a PRD of diabetic nephro-
pathy in contrast to 58% of those with T2DM
(P<0.001, Chi-squared test) (Figure 2). Primary
glomerulonephritis, interstitial nephritis and multi-
system diseases comprised the PRDs for 28% of
individuals with T2DM.
Survival in those with diabetes receiving
RRT
The incident cohort for survival analysis comprised
841 people who had first received RRT from 2006 to
2011. Median survival time from initiation of RRT
was 3.84 years (95% CI 2.77, 4.62) in T1DM and
2.16 years (95% CI 1.92, 2.38) in T2DM. The un-
adjusted yearly survival rates following initiation of
RRT are shown in Table 2.
Analysis of survival by PRD was restricted to those
with T2DM (n=606) given that almost all people
with T1DM had a PRD of diabetic nephropathy.
Yearly survival for the first 4 years follow-up strati-
fied by PRD is shown in Table 3.
Discussion
This study presents a nationwide analysis of the cur-
rent burden of CKD5 and RRT in people with T1DM
and T2DM in Scotland. We have demonstrated the
current prevalence of CKD5 in T1DM and T2DM.
Diabetic nephropathy was the PRD in 91% of pa-
tients with T1DM but was the PRD in only 58% of
patients with T2DM.
Previous studies have tended to report incidence
of RRT in diabetes as opposed to prevalence.12,13 A
large European study comprising of 10 registries
showed a small increase in the incidence of RRT
for T1DM and a marked increase in the incidence
of RRT in T2DM between 1991 to 2000(4). UK regis-
try data showed 15.2% of prevalent patients had
diabetes as their PRD and 25% of new incident
patients.6 In contrast to these studies, our study
determined prevalence of RRT in patients with
diabetes and so allows quantification of the current
burden of RRT in diabetes on health services thereby
allowing future resource planning. It is estimated
that by 2030, the prevalence of diabetes will
have more than doubled.14 A crude estimate quan-
tifying the future burden to the National Health
Service in Scotland is that there will be a relative
increase in overall national demand for RRT of
22% purely due to increasing diabetes prevalence.
This assumes that the current ratio of T1DM to
T2DM and prevalence of CKD5 remains stable.
This, albeit rough calculation, is a stark indicator
of the possible future burden to the National
Health Service.
There have been few previous estimates of the
incidence or prevalence of CKD5 among diabetic
populations.13,15,16 Other older studies have deter-
mined the prevalence of advanced renal disease
in subjects with T1DM, using the presence of
macroalbuminuria to define advanced renal dis-
ease.17,18. Although indicative of advanced renal
disease, macroalbuminuria is not specific to, nor
required for, a diagnosis of CKD5.19 A large global
cross-sectional study showed only 24% of those
Table 1 Point prevalence of CKD5 (including RRT) in those with diabetes in Scotland by age and diabetes type
Age group (years) T1DM T2DM Both types
Total Number CKD5 Total number CKD5 Total number CKD5
Number % Number % Number %
18 635 4 0.63 8 0 0.00 643 4 0.62
19–35 5585 36 0.64 1064 7 0.66 6649 43 0.65
36–50 7140 141 1.97 16 696 71 0.43 23 836 212 0.89
51–65 4342 108 2.49 56 623 257 0.45 60 965 365 0.60
66–75 1231 21 1.71 52 198 331 0.63 53 429 352 0.66
>75 481 6 1.25 41 282 306 0.74 41 763 312 0.75
Total 19 414 316 1.63 167871 972 0.58 187 285 1288 0.69
130 S. Bell et al.





with CKD5 had macroalbuminuria.20 Our study dif-
fers from the existing literature as the presence of
CKD5 is based on eGFR measurements. Our results
therefore add reliable, nationwide estimates of the
current burden of CKD5 and RRT in people with
diabetes to existing knowledge.
We have shown that a greater proportion of
prevalent cases of CKD5 with T1DM were in receipt
Figure 2. Primary causes of renal disease in those with T1DM and T2DM receiving RRT. Among those with T2DM, multi-
system diseases comprise of the following: Renal vascular disease—type unspecified (32%); renal vascular disease due to
hypertension (no primary renal disease) (23%); myelomatosis/light chain deposit disease (11%); and renal vascular disease
due to other cause (11%).

















0 100.00 (100, 100) 100.00 (100, 100) 100.00 (100, 100) 100.00 (100, 100) 100.00 (100, 100)
1 74.04 (69.53, 78.84) 84.26 (72.49, 97.93) 79.40 (68.24, 92.38) 59.43 (50.48, 69.97) 70.68 (61.27, 81.54)
2 51.79 (46.42, 57.77) 66.64 (51.53, 86.19) 66.28 (53.22, 82.55) 42.80 (33.88, 54.08) 52.87 (42.49, 65.79)
3 35.65 (30.22, 42.07) 49.98 (32.98, 75.75) 40.03 (26.25, 61.04) 23.05 (15.36, 34.60) 36.00 (25.72, 50.40)
4 24.78 (19.60, 31.34) 44.43 (27.61, 71.49) 30.88 (17.66, 53.99) 17.96 (10.47, 30.82) 17.60 (9.03, 34.32)
Table 2 Survival by year from first RRT and type of diabetes
Years since first RRT Percentage alive (95% CI)
T1DM T2DM Both types
0 100.00 (100, 100) 100.00 (100, 100) 100.00 (100, 100)
1 83.8 (79.0, 89.0) 71.9 (68.4, 75.5) 75.0 (72.0, 78.0)
2 67.4 (61.0, 74.6) 52.1 (48.1, 56.5) 56.0 (52.5, 59.7)
3 54.8 (47.6, 63.2) 34.4 (30.3, 39.1) 39.6 (35.9, 43.7)
4 47.7 (39.7, 57.2) 24.2 (20.2, 29.0) 30.0 (26.2, 34.3)
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of RRT (83%) than prevalent cases of CKD5 and
T2DM (61%) but these differences were accounted
for once adjustment was made for age, sex and dia-
betes duration. Consistent with this, among those
with T2DM, people were more likely to receive
RRT if they were younger and male.21–24
The PRD of patients with T2DM displayed more
heterogeneity than in patients with T1DM. This is in
keeping with previous biopsy studies that have indi-
cated that T2DM is associated with a greater variety
of renal pathology.25–30 However, these biopsy
series have the inherent potential for selection
bias. This study provides valuable evidence of het-
erogeneity existing on a national scale. Although
renal biopsies to determine the PRD in patients
with diabetes and CKD are rarely performed if
diabetic nephropathy is clinically suspected, the
presence of minimal albuminuria, microscopic
haematuria, and the absence of diabetic retinop-
athy, refractory hypertension or rapidly decreasing
eGFR are some of the signs that would warrant the
consideration of an alternative underlying patho-
logical process and the need for renal biopsy.19
The PRD due to causes other than diabetic nephro-
pathy are therefore more frequently biopsy proven
and so it is likely that the heterogeneity seen in re-
ported PRDs represents true underlying variety in
renal disease pathology. It should be noted that in
patients with T2DM there are a greater proportion of
missing PRD (11% compared with 3% in T1DM) so
that estimates of the prevalence of each PRD are
somewhat less certain in those with T2DM than
T1DM. Nonetheless the broad picture of greater het-
erogeneity in type 2 than type 1 is clear.
We have included brief data on survival in pa-
tients on RRT to emphasize the ongoing poor prog-
nosis once patients have progressed to needing RRT.
In our cohort, the median survival time from initi-
ation of RRT was 3.84 years (95% CI 2.77, 4.62) in
T1DM and 2.16 years (95% CI 1.92, 2.38) in T2DM.
This, however, is not adjusted for age which would
account for this difference. Median survival for the
overall population of RRT recipients in Scotland was
4.1 years (95% CI 3.9, 4.2).31 As detailed by the UK
renal registry report, longer-term survival at younger
ages is worse in those with than those without dia-
betes as a PRD with the differences being less at
older ages.7
Unfortunately, in our study there were insufficient
data to quantify survival rates by individual PRD and
to test for significant differences in survival rates by
PRD. The observed survival rates in those with dia-
betic nephropathy were higher than for multisystem
diseases but lower than for primary glomeruloneph-
ritis and interstitial nephropathy. A larger dataset
would be required to define such differences with
any precision.
The strength of our study is that it is composed of
national renal and diabetes data. We have been able
to comprehensively capture people with T1DM and
T2DM in Scotland without selection bias creating
the largest study of CKD5 in a diabetic population.
The prevalence and trends of RRT resulting from
diabetic nephropathy as derived from national
renal registries can be used as a surrogate marker
for ESRD but these data omit those with ESRD
who are not receiving RRT. Our study has been
able to provide a direct estimate of the current
prevalence in all patients with diabetes in
Scotland. These findings can be transferred to dia-
betes patterns in other developed countries.
Limitations of our study include the difficulty
when describing the PRD. The physician caring for
the patient makes the assessment based on clinical
findings and laboratory tests and so this ultimately
remains a subjective assessment. The absence of
biopsy-proven PRD may give rise to misclassifica-
tion bias. This method, however, reflects current na-
tional clinical practice to which the results are
directly applicable. A further limitation of the study
is the lack of albuminuria data which are not, as yet,
available nationally.
In conclusion, we have provided a current na-
tional prevalence of CKD5 and RRT in patients
with diabetes. The data are useful in emphasizing
the heterogeneity of renal disease in T2DM and pro-
vide useful data on renal outcomes among those
with diabetes for examining future trends. The
prevalence of T2DM is expected to increase world-
wide and the incidence of people requiring RRT will
also increase dramatically. The increased preva-
lence will potentially place a significant strain on
future healthcare resources. These results, therefore,
urge the need for worldwide interventions focusing
on the prevention of both diabetes and progression
of renal disease as well as allowing future resource
planning.
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